Abstract:Introduction: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC.Methods: The role of the phosphoinositide 3-kinase/protein kinase B signal transducer and activator of transcription 3, epithelial-mesenchymal transition, and tripartite motif containing 21 in regulating PD-L1 expression after radiotherapy was investigated by small interfering-PD-L1 RNA transfection, immunohistochemistry, Western blot, and immunoprecipitation. The synergistic effect of radiotherapy and anti-PD-L1 antibody was evaluated in a mouse model. PD-L1 expression on tumor specimens was examined in a retrospective cohort of patients who received concurrent chemoradiotherapy.Results: PD-L1 expression was increased in vivo and in vitro after conventionally fractionated radiation. Radiotherapy in combination with anti-PD-L1 antibody synergistically enhanced antitumor immunity by promoting CD8-positive T cell infiltration and reducing the accumulation of myeloid derived suppressor cells and tumor-infiltrating regulatory T cells in a mouse model. Radiotherapy may up-regulate PD-L1 expression through the phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3 pathways. PD-L1 may also stimulate cell migration and facilitate the epithelial-mesenchymal transition process to induce radioresistance. Moreover, down-regulating PD-L1 could alleviate radioresistance' by promoting apoptosis. Intriguingly, patients with negative PD-L1 expression had a significantly higher objective response rate (88% versus 43.1% [p < 0.001]) and disease control rate (100% versus 86.2% [p = 0.026]) than those with positive PD-L1 expression after delivery of radiotherapy.Conclusions: Conventionally fractionated radiotherapy in combination with anti-PD-L1 antibody shows a synergistic antitumor immunity in NSCLC. Furthermore, PD-L1 expression may be a significant clinical predictive factor for treatment response to radiotherapy in NSCLC. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Radiotherapy and Immune Checkpoint Blockade: Potential Interactions and Future Directions.

Radiotherapy and Immunotherapy: a Beneficial Liaison?

The Intersection of Radiotherapy and Immunotherapy: Mechanisms and Clinical Implications.

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Angiogenesis and Immune Checkpoint Dual Blockade in Combination with Radiotherapy for Treatment of Solid Cancers: Opportunities and Challenges

The Reciprocity Between Radiotherapy and Cancer Immunotherapy

Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

The next chapter in immunotherapy and radiation combination therapy – cancer-specific perspectives

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Combining Radiation with Immunotherapy: The University of Pennsylvania Experience

Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework

Combination of Radiotherapy and Vaccination Overcomes Checkpoint Blockade Resistance

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

The Confluence of Radiotherapy and Immunotherapy.

Recent progress in the combination treatment of radiotherapy and PD-1/PD-L1 signaling blockade immunotherapy

Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging

Beyond Success: Unveiling the Hidden Potential of Radiotherapy and Immunotherapy in Solid Tumors

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy

Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiation

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment